drugset / Trial / NCT06674538

Clinical Trial to Treat Stage IV Cancer Patients

NCT06674538 ↗

Phase 1 Enrolling by invitation 12 enrolled Moonshot Antibodies
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to study the safety and effectiveness of investigational antibodies attacking certain areas on the surface of cancer cells so that the body can kill the cancer cells. The antibodies will be made in a laboratory from cells taken from each subject's tumor so they will be made specifically per subject. The first step is to take blood and tumor samples so that the laboratory can produce antibodies specific to each subject's tumor. During this process, the study team will identify specific areas on the cancer cells that are not normally present in healthy cells so that the antibodies can find the cancer cells that should be destroyed. The second step is to deliver the antibodies to each subject through a series of infusions.

Timeline

Start
2024-12-30
Primary completion
2027-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Moonshot antibodies Unknown — Other